These observations suggest that mutations leading to a loss of function for SOD1 are not tolerated in cancer cells harboring pre-existing mutations within RAD54B, BLM or CHEK2, and further support SOD1 as a strong candidate therapeutic target. This evidence concerns the gene CHEK2 and cancer.